Johnson & Johnson (JNJ) Change in Inventory (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Change in Inventory came in at $431.0 million in Q1 2026, up 195.21% year-on-year from $146.0 million in Q1 2025, and up 836.96% quarter-over-quarter from $46.0 million in Q4 2025.
Johnson & Johnson (JNJ) Change in Inventory (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Change in Inventory across 18 years of filings, most recently posting $431.0 million for Q1 2026.
- Change in Inventory for Q1 2026 came in at $431.0 million, up 195.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.7 billion (up 87.37% YoY), and the FY2025 annual result was $1.5 billion, up 28.55% from the prior year.
- Change in Inventory came in at $431.0 million for Q1 2026 at Johnson & Johnson, up from $46.0 million in the prior quarter.
- In the past five years, Change in Inventory ranged from a high of $1.3 billion in Q1 2023 to a low of -$124.0 million in Q4 2023.
- The 5-year median for Change in Inventory is $391.0 million (2024), against an average of $418.7 million.
- Across the five-year window, Change in Inventory tumbled 109.19% in 2023 and surged 195.21% in 2026, its largest moves.
- Johnson & Johnson's Change in Inventory stood at $600.0 million in 2022, then plunged by 120.67% to -$124.0 million in 2023, then jumped by 172.58% to $90.0 million in 2024, then plunged by 48.89% to $46.0 million in 2025, then jumped by 836.96% to $431.0 million in 2026.
- The last three Change in Inventory figures came in at $431.0 million (Q1 2026), $46.0 million (Q4 2025), and $748.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 431.00 Mn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 184.00 Mn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | - |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | -18.00 Mn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 52.00 Mn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | -14.00 Mn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | -95.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 431.00 Mn |
| Mar 29, 2026 | 431.00 Mn |
| Dec 28, 2025 | 46.00 Mn |
| Dec 28, 2025 | 46.00 Mn |
| Sep 28, 2025 | 748.00 Mn |
| Sep 28, 2025 | 748.00 Mn |
| Jun 29, 2025 | 510.00 Mn |
| Jun 29, 2025 | 510.00 Mn |
| Mar 30, 2025 | 146.00 Mn |
| Mar 30, 2025 | 146.00 Mn |
| Dec 29, 2024 | 90.00 Mn |
| Dec 29, 2024 | 90.00 Mn |
| Sep 29, 2024 | 299.00 Mn |
| Sep 29, 2024 | 299.00 Mn |
| Jun 30, 2024 | 391.00 Mn |
| Jun 30, 2024 | 391.00 Mn |
| Mar 31, 2024 | 348.00 Mn |
| Mar 31, 2024 | 348.00 Mn |
| Dec 31, 2023 | -124.00 Mn |
| Dec 31, 2023 | -124.00 Mn |